EXHIBIT 10.22
[GENAERA LOGO HERE]
October 31, 2001
Xxxxxx Institute for Cancer Research
000 Xxxxx Xxxxxx - 00xx xxxxx
Xxx Xxxx, XX 00000
Attention: Xx. Xxxxxx X. XxXxxxxxx, President
Dear Sirs:
Pursuant to Section 4.2(a) of the Second Research Agreement dated
December 20, 1999 between The Xxxxxx Institute for Cancer Research ( "LICR") and
Genaera Corporation (formerly named Magainin Pharmaceuticals Inc.) ("Genaera")
(the "Agreement") and our September 28, 2001 telephone conference, this letter
serves as notice of renewal of the Agreement, effective December 20, 2001 for a
two year period, ending on December 20, 2003.
Except as set forth below, the Agreement shall remain unchanged and
each provision contained therein shall remain in full force and effect.
1) The first sentence of section 4.2(a) shall read as follows: "The
Brussels Branch of LICR And Genaera shall undertake the research program as
described on the Workplan attached hereto as Attachment A over a period of two
years from December 20, 2001."
2) Section 5.1 shall read as follows: "In partial support of the cost
of the Second Research Program to be undertaken by LICR as set forth in
Attachment A, Genaera shall make the following payments to LICR:
Payment Date Payment Due
---------------- -----------
[**]
The above payments shall be adjusted by increases in the annual salary
costs in accordance with the Belgian Salary Index (Indice Sante) and laboratory
costs and overhead in accordance with the Belgian Consumer Price Index (Indice
Complet) based on December, 2001."
____________
** Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
--------------------------------------------------------------------------------
0000 Xxxxxx Xxxxx . Xxxxxxxx Xxxxxxx, XX 00000 . Tel:(000)000-0000
Fax:(000)000-0000
[GENAERA LOGO HERE]
To: Xxxxxx Institute for Cancer Research
October 31, 2001
Page 2
We look forward to a very productive working term on a very exciting
workplan to be executed by the LICR scientists in the Brussels branch.
Please indicate your agreement with the foregoing by signing and
returning a copy of this letter.
Best Regards,
/s/ Xxx X. Xxxxxx, M.D.
-----------------------
Xxx X. Xxxxxx, M.D.
President and CEO
RCL:meb
Encl.
ACCEPTANCE BY: Xxxxxx institute for Cancer Research Date:
/s/ Xxxxx X. Old, M.D. Nov. 6, 2001
------------------------------------ ------------
Xxxxx X. Old, M.D., Chief Executive Officer
/s/ Xxxxxx X. XxXxxxxxx, Xx. Nov. 6, 2001
------------------------------------- ------------
Xxxxxx X. XxXxxxxxx, Xx., President
________________
** Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
